Regeneron Pharmaceuticals, Inc. (REGN) C5 Complement Development Program Focusing on Cemdisiran and Pozelimab for Complement-Mediated Diseases - Slide

Regeneron Pharmaceuticals presented a slide deck in April 2026 detailing its C5 complement inhibitor development program targeting complement-mediated diseases. The program focuses on two key drugs: cemdisiran, an RNA interference (RNAi) therapy, and pozelimab, a monoclonal antibody, both designed to block the C5 protein. Cemdisiran is under investigation for rare conditions like paroxysmal nocturnal hemoglobinuria (PNH) and cold agglutinin disease (CAD), with ongoing Phase 2/3 trials. Pozelimab, a fully human antibody, is being evaluated for generalized myasthenia gravis (gMG) and other complement-driven disorders, with Phase 3 studies underway. The presentation highlights Regeneron’s strategic push into complement-mediated disease treatments, leveraging its RNAi and antibody platforms for precision therapies.